{"id":58241,"date":"2025-11-06T12:42:33","date_gmt":"2025-11-06T12:42:33","guid":{"rendered":"https:\/\/ibima.eu\/?page_id=58241"},"modified":"2026-10-27T09:02:00","modified_gmt":"2026-10-27T09:02:00","slug":"erdera-jtc-2027","status":"publish","type":"page","link":"https:\/\/ibima.eu\/es\/erdera-jtc-2027\/","title":{"rendered":"ERDERA &#8211; JTC 2027"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00bb1&#8243; admin_label=\u00bbsection\u00bb _builder_version=\u00bb4.25.1&#8243; custom_padding=\u00bb||0px|||\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_5,3_5,1_5&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb21px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][et_pb_column type=\u00bb3_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2025\/11\/erdera-logo-1.png\u00bb title_text=\u00bberdera logo\u00bb align=\u00bbcenter\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb54%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb26px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb59px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbERDERA Preanuncio \u2013 Call for Proposals 2027: Catalysing Collaborative Research for Recently Identified Rare Diseases\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#0C71C3&#8243; title_line_height=\u00bb1.3em\u00bb module_alignment=\u00bbcenter\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb20px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.7&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb1px|-78px|||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p data-pm-slice=\"1 1 []\" style=\"text-align: justify;\">La European Rare Diseases Research Alliance (ERDERA) tiene previsto lanzar el 1 de diciembre de 2026 la convocatoria internacional Joint Transnational Call (JTC) 2027, centrada en impulsar la investigaci\u00f3n colaborativa sobre enfermedades raras identificadas recientemente y todav\u00eda insuficientemente estudiadas, con el objetivo de generar el conocimiento cient\u00edfico necesario para facilitar el futuro desarrollo de tratamientos.<\/p>\n<p>[\/et_pb_text][et_pb_heading title=\u00bbObjetivos de la convocatoria\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=\u00bbrow\u00bb _builder_version=\u00bb4.27.7&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb77.1%\u00bb custom_margin=\u00bb|-259px|1px|161px|false|false\u00bb custom_padding=\u00bb|0px||9px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.16&#8243; custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.7&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb11px|-78px|||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p data-pm-slice=\"1 3 []\" style=\"text-align: justify;\"><span>El objetivo de esta convocatoria es promover colaboraciones internacionales e interdisciplinares que permitan avanzar en el conocimiento de enfermedades raras recientemente identificadas, especialmente aquellas que todav\u00eda carecen de informaci\u00f3n suficiente sobre su historia natural, mecanismos fisiopatol\u00f3gicos, biomarcadores o modelos experimentales.<\/span><\/p>\n<p style=\"text-align: justify;\"><strong><span>Los proyectos deber\u00e1n abordar al menos una de las siguientes \u00e1reas:<\/span><\/strong><\/p>\n<ul data-spread=\"false\">\n<li style=\"list-style-type: none;\">\n<ul data-spread=\"false\">\n<li style=\"text-align: justify;\"><strong><span>Estudios de historia natural y registros de pacientes:<\/span><\/strong><span> caracterizaci\u00f3n de la evoluci\u00f3n de la enfermedad, desarrollo de registros y estudios que faciliten la preparaci\u00f3n de futuros ensayos cl\u00ednicos.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Identificaci\u00f3n y validaci\u00f3n de biomarcadores:<\/span><\/strong><span> investigaci\u00f3n de biomarcadores asociados a la fisiopatolog\u00eda o progresi\u00f3n de la enfermedad, estratificaci\u00f3n de pacientes, caracterizaci\u00f3n de la historia natural y preparaci\u00f3n de futuros ensayos cl\u00ednicos. No se incluye el desarrollo de pruebas diagn\u00f3sticas cl\u00ednicas.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Desarrollo de modelos de enfermedad:<\/span><\/strong><span> generaci\u00f3n y caracterizaci\u00f3n de modelos <\/span><em><span>in silico<\/span><\/em><span>, celulares y modelos animales que reproduzcan adecuadamente las caracter\u00edsticas de la enfermedad humana.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Estudio de mecanismos fisiopatol\u00f3gicos:<\/span><\/strong><span> identificaci\u00f3n y caracterizaci\u00f3n de v\u00edas moleculares y mecanismos implicados en el desarrollo de la enfermedad que puedan orientar futuras estrategias terap\u00e9uticas.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul data-spread=\"false\" style=\"text-align: justify;\"><\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb-4px|auto||159px|false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbRequisitos espec\u00edficos de las enfermedades elegibles\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb88px\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p data-pm-slice=\"1 1 []\" style=\"text-align: justify;\">Las enfermedades objeto de estudio deber\u00e1n cumplir simult\u00e1neamente los siguientes requisitos:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Haber sido descritas por primera vez en publicaciones cient\u00edficas revisadas por pares a partir del <strong>1 de enero de 2010<\/strong>, incluyendo una asociaci\u00f3n con un posible mecanismo causal (por ejemplo, una asociaci\u00f3n gen-enfermedad). Ser\u00e1 necesario aportar el PMID o DOI de la publicaci\u00f3n original.<\/li>\n<li>Estar registradas en <strong>Orphanet<\/strong> o encontrarse en proceso de registro en el momento de presentar la solicitud. En este \u00faltimo caso, deber\u00e1 aportarse evidencia de haber solicitado el registro.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Los proyectos podr\u00e1n centrarse en una \u00fanica enfermedad o en un grupo reducido de enfermedades estrechamente relacionadas, siempre que todas cumplan individualmente ambos requisitos.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb35px|auto||159px|false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbTemas y enfoques excluidos\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb88px\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\"><span>Enfermedades para las que ya se hayan desarrollado y caracterizado modelos animales en publicaciones cient\u00edficas revisadas por pares.<\/span><\/li>\n<li style=\"text-align: justify;\"><span>Enfermedades para las que existan ensayos cl\u00ednicos en curso o finalizados que eval\u00faen tratamientos modificadores de la enfermedad.<\/span><\/li>\n<li style=\"text-align: justify;\"><span>Estudios de desarrollo precl\u00ednico de terapias (\u00e1mbito de la convocatoria ERDERA JTC2025).<\/span><\/li>\n<li style=\"text-align: justify;\"><span>Estudios dirigidos al desarrollo de herramientas diagn\u00f3sticas (\u00e1mbito de ERDERA JTC2026). No se excluye la caracterizaci\u00f3n funcional de variantes ni la caracterizaci\u00f3n fenot\u00edpica cuando sean necesarias para comprender los mecanismos de enfermedad.<\/span><\/li>\n<li style=\"text-align: justify;\"><span>Ensayos cl\u00ednicos intervencionistas.<\/span><\/li>\n<li style=\"text-align: justify;\"><span>Proyectos centrados exclusivamente en enfermedades neurodegenerativas raras incluidas en el \u00e1mbito de la <\/span><em><span>Brain Health Partnership<\/span><\/em><span> (Alzheimer y otras demencias, Parkinson y trastornos relacionados, enfermedades pri\u00f3nicas, enfermedades de motoneurona, Huntington, atrofia muscular espinal y formas dominantes de ataxia espinocerebelosa). <\/span><strong><span>Las demencias infantiles y enfermedades neurodegenerativas pedi\u00e1tricas s\u00ed son elegibles.<\/span><\/strong><\/li>\n<li style=\"text-align: justify;\"><span>Enfermedades infecciosas raras, c\u00e1nceres raros y acontecimientos adversos raros asociados a tratamientos de enfermedades comunes. <\/span><strong><span>S\u00ed son elegibles las enfermedades raras con predisposici\u00f3n al c\u00e1ncer y los errores innatos de la inmunidad o enfermedades con predisposici\u00f3n gen\u00e9tica a infecciones raras.<\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb14px|auto|-13px|159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbCondiciones generales\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\"><strong><span>Pa\u00edses participantes previstos:<\/span><\/strong><span> Austria, B\u00e9lgica, Bulgaria, Canad\u00e1, Rep\u00fablica Checa, Estonia, Francia, Hungr\u00eda, Irlanda, Italia, Letonia, Lituania, Luxemburgo, Noruega, Polonia, Portugal, Ruman\u00eda, Eslovaquia, Espa\u00f1a, Suecia, Suiza y Turqu\u00eda.<\/span><span><\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Financiaci\u00f3n espa\u00f1ola:<\/span><\/strong><span> participaci\u00f3n prevista del Instituto de Salud Carlos III (ISCIII). Los requisitos espec\u00edficos de elegibilidad y financiaci\u00f3n nacional est\u00e1n pendientes de publicaci\u00f3n.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>M\u00ednimo:<\/span><\/strong><span> 3 socios investigadores elegibles de al menos 3 pa\u00edses diferentes participantes.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>M\u00e1ximo:<\/span><\/strong><span> 6 socios investigadores financiados, ampliables excepcionalmente a 8 mediante la incorporaci\u00f3n de socios de pa\u00edses infrarrepresentados (<\/span><em><span>Underrepresented Countries<\/span><\/em><span>, UC) y\/o investigadores en etapas iniciales de su carrera (<\/span><em><span>Early-Career Researchers<\/span><\/em><span>, ECR).<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Consorcios de 7 socios:<\/span><\/strong><span> deber\u00e1n incorporar al menos un socio UC o ECR.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Consorcios de 8 socios:<\/span><\/strong><span> deber\u00e1n incorporar dos socios adicionales de estas categor\u00edas (2 UC, 2 ECR o 1 UC + 1 ECR).<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>M\u00e1ximo de 2 socios investigadores elegibles por pa\u00eds.<\/span><\/strong><\/li>\n<li style=\"text-align: justify;\"><strong><span>Participaci\u00f3n de pacientes:<\/span><\/strong><span> se espera que los consorcios involucren activamente a representantes de pacientes desde la preparaci\u00f3n de la propuesta. Estos socios no computan en el l\u00edmite de socios investigadores.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Procedimiento:<\/span><\/strong><span> convocatoria en dos fases, con presentaci\u00f3n inicial de <\/span><em><span>pre-proposals<\/span><\/em><span> y posterior invitaci\u00f3n a presentar <\/span><em><span>full proposals<\/span><\/em><span>.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Duraci\u00f3n y presupuesto:<\/span><\/strong><span> pendientes de confirmaci\u00f3n en la documentaci\u00f3n definitiva.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb min_height=\u00bb317px\u00bb custom_margin=\u00bb20px|auto||159px|false|false\u00bb custom_padding=\u00bb||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbfechas clave\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243; min_height=\u00bb259px\u00bb]<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"text-align: justify;\"><strong><span>1 de diciembre de 2026:<\/span><\/strong><span> apertura prevista de la convocatoria.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>14 de diciembre de 2026 (15:00\u201316:00 CET):<\/span><\/strong><span> <\/span><em><span>webinar<\/span><\/em><span> informativo para solicitantes.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>1 de febrero de 2027:<\/span><\/strong><span> fecha l\u00edmite para el env\u00edo de <\/span><em><span>pre-proposals<\/span><\/em><span>.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>18 de febrero de 2027:<\/span><\/strong><span> comprobaci\u00f3n de elegibilidad de <\/span><em><span>pre-proposals<\/span><\/em><span>.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Mediados de abril de 2027:<\/span><\/strong><span> invitaci\u00f3n a presentar <\/span><em><span>full proposals<\/span><\/em><span>.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Finales de abril\/principios de mayo de 2027:<\/span><\/strong><span> <\/span><em><span>webinar<\/span><\/em><span> informativo para solicitantes invitados a la segunda fase.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>24 de junio de 2027:<\/span><\/strong><span> fecha l\u00edmite para el env\u00edo de <\/span><em><span>full proposals<\/span><\/em><span>.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>15 de julio de 2027:<\/span><\/strong><span> comprobaci\u00f3n de elegibilidad de <\/span><em><span>full proposals<\/span><\/em><span>.<\/span><\/li>\n<li style=\"text-align: justify;\"><strong><span>Finales de octubre de 2027:<\/span><\/strong><span> comunicaci\u00f3n de los resultados de financiaci\u00f3n.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul><\/ul>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb-23px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbDocumentaci\u00f3n y enlaces clave\u00bb _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb-17px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.7&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb|||11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><strong><a href=\"https:\/\/erdera.org\/call\/joint-transnational-call-2027\/\"><span>Web oficial ERDERA \u2013 JTC 2027<\/span><\/a><\/strong><strong><\/strong><\/li>\n<li><strong><a href=\"https:\/\/erdera.org\/publications\/erdera-2027-joint-transnational-call-pre-announcement\/\"><span>Preanuncio oficial ERDERA JTC 2027<\/span><\/a><\/strong><strong><\/strong><\/li>\n<li><strong><a href=\"https:\/\/erdera.org\/news\/erdera-pre-announces-2027-joint-transnational-call-on-recently-identified-rare-diseases\/\"><span>Noticia de presentaci\u00f3n de la convocatoria<\/span><\/a><\/strong><strong><\/strong><\/li>\n<li><strong><a href=\"https:\/\/erdera.org\/event\/information-webinar-erdera-joint-transnational-call-2027\/\"><span>Webinar informativo \u2013 14 de diciembre de 2026<\/span><\/a><\/strong><strong><\/strong><\/li>\n<li><strong><a href=\"https:\/\/www.orpha.net\/\"><span>O<\/span><\/a><\/strong><strong><a href=\"https:\/\/www.orpha.net\/\"><span>rphanet \u2013 Portal de enfermedades rara<\/span><\/a><\/strong>\n<ul><\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#195e7f\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,1_4,1_4,1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2023\/04\/Logoblancofondoazul.jpg\u00bb title_text=\u00bbLogoblancofondoazul\u00bb force_fullwidth=\u00bbon\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb transform_scale_tablet=\u00bb202%|202%\u00bb transform_scale_phone=\u00bb202%|202%\u00bb transform_scale_last_edited=\u00bbon|tablet\u00bb transform_translate_tablet=\u00bb75px|25px\u00bb transform_translate_phone=\u00bb85px|-15px\u00bb transform_translate_last_edited=\u00bbon|phone\u00bb transform_translate_linked_tablet=\u00bboff\u00bb transform_rotate_tablet=\u00bb\u00bb transform_rotate_phone=\u00bb\u00bb transform_rotate_last_edited=\u00bbon|tablet\u00bb transform_skew_tablet=\u00bb\u00bb transform_skew_phone=\u00bb\u00bb transform_skew_last_edited=\u00bbon|tablet\u00bb transform_origin_tablet=\u00bb\u00bb transform_origin_phone=\u00bb\u00bb transform_origin_last_edited=\u00bbon|tablet\u00bb transform_styles_last_edited=\u00bbon|phone\u00bb min_height_tablet=\u00bb\u00bb min_height_phone=\u00bb\u00bb min_height_last_edited=\u00bbon|desktop\u00bb custom_margin_tablet=\u00bb||0px|-5px|false|false\u00bb custom_margin_phone=\u00bb||30px|-17px|false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb custom_padding=\u00bb|200px|||false|false\u00bb custom_padding_tablet=\u00bb0px|200px|||false|false\u00bb custom_padding_phone=\u00bb|200px|||false|false\u00bb custom_padding_last_edited=\u00bbon|desktop\u00bb transform_styles_tablet=\u00bb\u00bb transform_styles_phone=\u00bb\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb14px|||-11%|false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p class=\"x_MsoNormal\" style=\"text-align: left;\"><span style=\"color: #ffffff;\"><img decoding=\"async\" src=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png\" width=\"20\" style=\"position: relative; top: 3px; left: -5px; float: left;\" \/>Avenida Severo Ochoa, 35, 29590, M\u00e1laga<\/span><\/p>\n<p style=\"color: #ffffff;\"><img decoding=\"async\" src=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/phone.png\" width=\"20\" style=\"position: relative; top: 3px; left: -5px;\" \/>952 36 76 00<\/p>\n<p><a href=\"mailto:info@ibima.eu\" data-linkindex=\"0\" id=\"LPlnk315329\"><img decoding=\"async\" src=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/email.png\" width=\"20\" style=\"position: relative; top: 3px; left: -5px;\" \/>info@ibima.eu<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][dsm_menu title=\u00bbAPARTADOS PRINCIPALES\u00bb menu_id=\u00bb1332&#8243; menu_link_text_color=\u00bb#FFFFFF\u00bb active_link_color=\u00bb#FFFFFF\u00bb menu_link_text_active_color=\u00bb#FFFFFF\u00bb menu_link_text_visited_color=\u00bb#FFFFFF\u00bb list_style_type=\u00bbnone\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_align=\u00bbleft\u00bb header_text_color=\u00bb#FFFFFF\u00bb header_font_size=\u00bb20px\u00bb custom_margin_tablet=\u00bb200px||||false|false\u00bb custom_margin_phone=\u00bb0px||||false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_menu][\/et_pb_column][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][dsm_menu title=\u00bbTEXTOS LEGALES\u00bb menu_id=\u00bb1333&#8243; menu_link_text_color=\u00bb#FFFFFF\u00bb active_link_color=\u00bb#FFFFFF\u00bb menu_link_text_active_color=\u00bb#FFFFFF\u00bb menu_link_text_visited_color=\u00bb#FFFFFF\u00bb list_style_type=\u00bbnone\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_align=\u00bbleft\u00bb header_text_color=\u00bb#FFFFFF\u00bb header_font_size=\u00bb20px\u00bb custom_margin_tablet=\u00bb-155px||||false|false\u00bb custom_margin_phone=\u00bb0px||||false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_menu][\/et_pb_column][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_social_media_follow _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin_tablet=\u00bb5px||||false|false\u00bb custom_margin_phone=\u00bb5px||||false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_social_media_follow_network social_network=\u00bbtwitter\u00bb url=\u00bbhttps:\/\/x.com\/_ibima?lang=es%20&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#000000&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]twitter[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bbfacebook\u00bb url=\u00bbhttps:\/\/www.facebook.com\/Ibima.eu\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#3b5998&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]facebook[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bbinstagram\u00bb url=\u00bbhttps:\/\/www.instagram.com\/ibima_mlg\/\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#ea2c59&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]instagram[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bblinkedin\u00bb url=\u00bbhttps:\/\/es.linkedin.com\/company\/ibima\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#007bb6&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]linkedin[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bbyoutube\u00bb url=\u00bbhttps:\/\/www.youtube.com\/channel\/UCY3UUZTi9X0ur-1Gd6MKonw\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#a82400&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]youtube[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][dsm_icon_list _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbBuz\u00f3n de sugerencias\u00bb font_icon=\u00bb&#x3d;||divi||400&#8243; icon_color=\u00bb#FFFFFF\u00bb url=\u00bbhttps:\/\/ibima.eu\/es\/comunicacion-con-el-instituto\/\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.2&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list_child][dsm_icon_list_child text=\u00bbBuz\u00f3n de denuncias\u00bb font_icon=\u00bb&#x3d;||divi||400&#8243; icon_color=\u00bb#FFFFFF\u00bb url=\u00bbhttps:\/\/ibima.eu\/es\/canal-de-denuncias\/\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list_child][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbSuscr\u00edbete al Canal de Divulgaci\u00f3n\u00bb font_icon=\u00bb&#x3d;||divi||400&#8243; icon_color=\u00bb#FFFFFF\u00bb url=\u00bbhttps:\/\/forms.gle\/5mczd4KKMqkBPdBy7&#8243; url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list_child][\/dsm_icon_list][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La European Rare Diseases Research Alliance (ERDERA) tiene previsto lanzar el 1 de diciembre de 2026 la convocatoria internacional Joint Transnational Call (JTC) 2027, centrada en impulsar la investigaci\u00f3n colaborativa sobre enfermedades raras identificadas recientemente y todav\u00eda insuficientemente estudiadas, con el objetivo de generar el conocimiento cient\u00edfico necesario para facilitar el futuro desarrollo de tratamientos.El [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-58241","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ERDERA - JTC 2027 - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/erdera-jtc-2027\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ERDERA - JTC 2027 - Ibima\" \/>\n<meta property=\"og:description\" content=\"La European Rare Diseases Research Alliance (ERDERA) tiene previsto lanzar el 1 de diciembre de 2026 la convocatoria internacional Joint Transnational Call (JTC) 2027, centrada en impulsar la investigaci\u00f3n colaborativa sobre enfermedades raras identificadas recientemente y todav\u00eda insuficientemente estudiadas, con el objetivo de generar el conocimiento cient\u00edfico necesario para facilitar el futuro desarrollo de tratamientos.El [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/erdera-jtc-2027\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T09:02:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/erdera-jtc-2027\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/erdera-jtc-2027\\\/\",\"name\":\"ERDERA - JTC 2027 - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/erdera-jtc-2027\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/erdera-jtc-2027\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/contact.png\",\"datePublished\":\"2025-11-06T12:42:33+00:00\",\"dateModified\":\"2026-10-27T09:02:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/erdera-jtc-2027\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/erdera-jtc-2027\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/erdera-jtc-2027\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/contact.png\",\"contentUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/contact.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/erdera-jtc-2027\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ERDERA &#8211; JTC 2027\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ERDERA - JTC 2027 - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/erdera-jtc-2027\/","og_locale":"es_ES","og_type":"article","og_title":"ERDERA - JTC 2027 - Ibima","og_description":"La European Rare Diseases Research Alliance (ERDERA) tiene previsto lanzar el 1 de diciembre de 2026 la convocatoria internacional Joint Transnational Call (JTC) 2027, centrada en impulsar la investigaci\u00f3n colaborativa sobre enfermedades raras identificadas recientemente y todav\u00eda insuficientemente estudiadas, con el objetivo de generar el conocimiento cient\u00edfico necesario para facilitar el futuro desarrollo de tratamientos.El [&hellip;]","og_url":"https:\/\/ibima.eu\/es\/erdera-jtc-2027\/","og_site_name":"Ibima","article_modified_time":"2026-10-27T09:02:00+00:00","og_image":[{"url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/erdera-jtc-2027\/","url":"https:\/\/ibima.eu\/erdera-jtc-2027\/","name":"ERDERA - JTC 2027 - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibima.eu\/erdera-jtc-2027\/#primaryimage"},"image":{"@id":"https:\/\/ibima.eu\/erdera-jtc-2027\/#primaryimage"},"thumbnailUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png","datePublished":"2025-11-06T12:42:33+00:00","dateModified":"2026-10-27T09:02:00+00:00","breadcrumb":{"@id":"https:\/\/ibima.eu\/erdera-jtc-2027\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/erdera-jtc-2027\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ibima.eu\/erdera-jtc-2027\/#primaryimage","url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png","contentUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/erdera-jtc-2027\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"ERDERA &#8211; JTC 2027"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/pages\/58241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=58241"}],"version-history":[{"count":8,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/pages\/58241\/revisions"}],"predecessor-version":[{"id":63909,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/pages\/58241\/revisions\/63909"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=58241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}